Analyzing RTI Surgical (RTIX) & Trivascular Technologies (TRIV)

RTI Surgical (NASDAQ: RTIX) and Trivascular Technologies (NASDAQ:TRIV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Valuation and Earnings

This table compares RTI Surgical and Trivascular Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RTI Surgical $272.86 million 0.96 -$14.39 million ($0.07) -61.43
Trivascular Technologies N/A N/A N/A ($2.88) -2.04

Trivascular Technologies has lower revenue, but higher earnings than RTI Surgical. RTI Surgical is trading at a lower price-to-earnings ratio than Trivascular Technologies, indicating that it is currently the more affordable of the two stocks.


This table compares RTI Surgical and Trivascular Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RTI Surgical 1.01% 2.29% 1.06%
Trivascular Technologies -143.61% -766.90% -66.97%

Analyst Recommendations

This is a breakdown of current ratings and price targets for RTI Surgical and Trivascular Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RTI Surgical 0 0 0 0 N/A
Trivascular Technologies 0 0 0 0 N/A

Insider & Institutional Ownership

69.9% of RTI Surgical shares are held by institutional investors. 4.9% of RTI Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


RTI Surgical beats Trivascular Technologies on 7 of the 8 factors compared between the two stocks.

RTI Surgical Company Profile

RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.

Trivascular Technologies Company Profile

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with's FREE daily email newsletter.

Leave a Reply